Aqara Announces Availability of its Smoke Detector in Europe
Aqara, a global leader and pioneer in IoT, rounds out its home safety solutions today with the release of its Smoke Detector across the European market. This new sensor is packed with smart features and broad compatibility across smart home platforms, ensuring comprehensive protection by alerting homeowners to the first sign of smoke and enabling swift action to mitigate potential damage.
Equipped with a powerful siren, the Aqara Smoke Detector triggers an alarm of up to 85 decibels and a LED indicator that flashes red at the first detection of smoke. In addition, it triggers all siren-equipped Aqara hubs and other grouped Aqara smoke detectors throughout the home, alerting family members in every room.
Even when away from home, homeowners receive real-time alerts directly to their smartphones, allowing prompt action from any location. With Aqara’s indoor cameras, users can verify the alarm remotely, reducing the chance of false alarms. The Aqara Smoke Detector gives homeowners peace of mind knowing their properties and families are safeguarded, no matter where they are. Users with multiple properties or elderly family members who live in a separate home can monitor multiple locations with ease.
In the event of a false alarm, users can quickly silence loud sirens through the Aqara Home app, offering immediate relief without disarming the fire alarm. For added flexibility and convenience, users can also mute the alarm by pressing a connected Wireless Mini Switch or even showing a preset gesture to the Camera Hub G3. Full disarmament requires pressing the reset button on the device.
The Smoke Detector integrates seamlessly with major platforms including Amazon Alexa, Apple Home, and Google Home, and supports Matter-over-Bridge for future-proofed interoperability*. This allows the sensor to work with smart devices from Aqara and other brands, enhancing the home safety system’s functionality. For example, in case of smoke detection, RGB smart lights can flash red to visually alert home residents, or the HVAC system can shut down to prevent smoke from spreading.
Built upon the Zigbee protocol, the Aqara Smoke Detector minimizes maintenance with an ultra-long battery life of up to 10 years. Its sleek, compact design blends into any home decor while allowing rapid response in emergencies. Low-battery notifications ensure the uninterrupted protection, and users can perform self-tests through the Aqara Home app to maintain optimal functionality.
The Aqara Smoke Detector underscores the company’s dedication to innovative, user-centered designs that redefine home safety and automation. Aqara remains at the forefront of smart home technology that blends seamlessly into modern lifestyles while enhancing safety, convenience and overall quality of life.
The Aqara Smoke Detector is now available in Europe through select Aqara retailers. Availability at Amazon brand stores is expected in the coming weeks.
For more information on this sensor, please visit our website.
* An Aqara hub is required for use of the Smoke Detector. A Matter-compatible Aqara hub is required for Matter compatibility, though some smart home platforms may not support smoke detectors via Matter by the time of launch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119164474/en/
Contacts
For Media Inquiries:
media@aqara.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom